Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Puma Biotechnology Inc    PBYI

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
The feature you requested does not exist. However, we suggest the following feature:

PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/20/2016 | 01:38pm CEST

PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item3.01

Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.

On December15, 2016, the Board of Directors of Puma
Biotechnology, Inc. (the Company) authorized the Company to
transfer the listing of its common stock, par value $0.0001 per
share (Common Stock), from The New York Stock Exchange (the NYSE)
to The NASDAQ Stock Market (NASDAQ). On December19, 2016, the
Company provided written notice to the NYSE of its intention to
voluntarily delist its Common Stock from the NYSE and to list its
Common Stock on NASDAQ. The Company expects the listing and
trading of its Common Stock on the NYSE to cease at the close of
trading on December30, 2016 and that trading of its Common stock
will commence on NASDAQ on the next business day, January3, 2017.
The Companys Common Stock has been approved for listing on NASDAQ
and will continue to trade under the stock symbol PBYI.

A copy of the press release issued by the Company in connection
with the transfer of the listing of its Common Stock from the
NYSE to NASDAQ is attached hereto as Exhibit 99.1 and is
incorporated herein by reference.

Item9.01 Financial Statements and Exhibits.
(d) Exhibits.
99.1 Press Release dated December19, 2016

About PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI)
Puma Biotechnology, Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the global development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), which the Company is developing for the treatment of patients with human epidermal growth factor receptor type 2 (HER2), positive breast cancer, and patients with non-small cell lung cancer, breast cancer and other solid tumors that have a HER2 mutation; PB272 (neratinib (intravenous)), which the Company is developing for the treatment of patients with advanced cancer, and PB357, which is an orally administered agent. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors (EGFRs), HER1, HER2 and HER4. PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Recent Trading Information
PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) closed its last trading session down -1.20 at 35.05 with 539,945 shares trading hands.

The post PUMA BIOTECHNOLOGY, INC. (NYSE:PBYI) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing appeared first on Market Exclusive.

© Market Exclusive 2016, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PUMA BIOTECHNOLOGY INC
04/20 PUMA BIOTECHNOLOGY : Caligor to Support Puma Biotechnology's Expanded Access Pro..
04/19 PUMA BIOTECHNOLOGY, INC. (NASDAQ : PBYI) Files An 8-K Other Events
04/19 PUMA BIOTECHNOLOGY, INC. : Other Events (form 8-K)
04/18 PUMA BIOTECHNOLOGY : Expands Neratinib Access to HER2+ Breast Cancer Patients In..
04/18 HERE’S WHY PUMA BIOTECHNOLOGY : PBYI) Is Running Up
04/17 PUMA BIOTECHNOLOGY : Announces FDA Advisory Committee to Review Neratinib for th..
04/06 PUMA BIOTECHNOLOGY, INC. (NASDAQ : PBYI) Files An 8-K Other Events
04/06 PUMA BIOTECHNOLOGY, INC. : Other Events (form 8-K)
04/04 PUMA BIOTECHNOLOGY : Presents Interim Results of Phase II CONTROL Trial of PB272..
04/02 PUMA BIOTECHNOLOGY : Presents Interim Results of Phase Ib/II FB-10 Trial of PB27..
More news
Sector news : Biotechnology & Medical Research - NEC
04/22DJNovartis Tests New Alzheimer's Drug on People Who Don't Have the Disease
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
01/03 Adam Feuerstein's 17 thoughts for biotech in 17
2016 Mid-stage data on therapeutic approach to managing neratinib-associated diarr..
2016 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
2016 Puma Bio launches ex-U.S. patient access program for neratinib
2016 INVESTOR SENTIMENT VS. SELLSIDE CONS : A Chicken And Egg Situation
Advertisement
Financials ($)
Sales 2017 28,8 M
EBIT 2017 -327 M
Net income 2017 -341 M
Finance 2017 242 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 39,2x
EV / Sales 2018 5,94x
Capitalization 1 373 M
More Financials
Chart PUMA BIOTECHNOLOGY INC
Duration : Period :
Puma Biotechnology Inc Technical Analysis Chart | PBYI | US74587V1070 | 4-Traders
Full-screen chart
Technical analysis trends PUMA BIOTECHNOLOG...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 79,0 $
Spread / Average Target 113%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alan H. Auerbach Chairman, President, CEO & Secretary
Charles R. Eyler Treasurer & Senior VP-Finance & Administration
Richard Paul Bryce Senior VP-Clinical Research & Development
Jay M. Moyes Independent Director
Troy E. Wilson Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PUMA BIOTECHNOLOGY INC2.61%1 373
INCYTE CORPORATION22.68%25 166
QUINTILES IMS HOLDINGS..8.15%19 405
LONZA GROUP AG8.28%11 101
CELLTRION, INC.--.--%9 762
SEATTLE GENETICS, INC.23.82%9 319
More Results